BT7480 + nivolumab

**BT7480 + nivolumab** is an investigational combination therapy for advanced solid tumors, specifically those associated with Nectin-4 expression. **BT7480** is a first-in-class, fully synthetic tumor-targeted immune cell agonist built from three bicyclic peptides (Bicycle®): one targeting Nectin-4 (a tumor antigen) and two targeting CD137 (also known as 4-1BB, a T-cell costimulatory receptor). This structure allows for colocalized binding of Nectin-4 on tumor cells and CD137 on immune cells, promoting localized immune activation within the tumor microenvironment. **Nivolumab** is a monoclonal antibody against the programmed death-1 (PD-1) immune checkpoint, enhancing antitumor immune responses by blocking inhibitory signaling in T cells. The combination is under clinical investigation for safety, pharmacokinetics, and preliminary efficacy, particularly focusing on immune activation and antitumor activity in patients with advanced, refractory solid tumors overexpressing Nectin-4[1][2][3][4][5].

Other names

BT7480 and nivolumabBT-7480 and nivolumabBT 7480 and nivolumabBT7480 plus nivolumabBT-7480 plus nivolumabBT 7480 plus nivolumab